BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Browsing Tag

T Cell Receptors

2 posts

T-cell receptor (TCR) is a protein complex found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules.

The human body’s own immune system has nearly limitless capacity to detect abnormalities. This ability is achieved by the related structures of two molecules, immunoglobulins and T cell receptors (TCR).

The TCR, a defining structure of T cells, is a transmembrane heterodimer consisting of either an alpha and beta chain or delta and gamma chain linked by a disulphide bond. Within these chains are complementary determining regions (CDRs) which determine the antigen to which the TCR will bind. TCRs activate the T cells in which they reside leading to a plethora of immune responses. Harnessing the power of this response and of TCR specificity is leading to a new generation of extremely promising immunotherapies.

Celyad-Oncology-Pauses-CYAD-101-002-Keynote-B79-Phase-1-Trial-After-2-Deaths-Reported
BioTech Health X
  • March 7, 2022

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

  • 2 minute read
Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…
0 Shares
0
0
0
0
0
0
0
Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery T Cell Receptors
BioTech Health X
  • May 4, 2021

Biotech NewsRepertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors

  • 3 minute read
The collaboration between Repertoire and Yale seeks to identify novel antigenic reactivity of T cells in patients with…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
  • CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
  • Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
  • SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 19, 2022
    Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
    Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
    • September 14, 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    • September 3, 2022
    Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
    Mayo-Clinic-Gene-Accelerator
    • September 2, 2022
    SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
    SyneuRx CEO Interview Dr Emil Tsai BioTech Health X
    • August 1, 2022
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • July 28, 2022
  • Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    • July 22, 2022
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • July 20, 2022
Categories
  • BioTech CEO Interviews (4)
  • Biotech News (44)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top